PE20231841A1 - Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral - Google Patents
Coagonistas de los receptores glp-1 y gip adecuados para el suministro oralInfo
- Publication number
- PE20231841A1 PE20231841A1 PE2023000026A PE2023000026A PE20231841A1 PE 20231841 A1 PE20231841 A1 PE 20231841A1 PE 2023000026 A PE2023000026 A PE 2023000026A PE 2023000026 A PE2023000026 A PE 2023000026A PE 20231841 A1 PE20231841 A1 PE 20231841A1
- Authority
- PE
- Peru
- Prior art keywords
- absent
- glp
- coagonists
- peptide
- gip
- Prior art date
Links
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 3
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001408 amides Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055026P | 2020-07-22 | 2020-07-22 | |
| EP20192414 | 2020-08-24 | ||
| US202163156988P | 2021-03-05 | 2021-03-05 | |
| PCT/EP2021/070485 WO2022018186A1 (en) | 2020-07-22 | 2021-07-22 | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231841A1 true PE20231841A1 (es) | 2023-11-21 |
Family
ID=77179985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023000026A PE20231841A1 (es) | 2020-07-22 | 2021-07-22 | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20220177538A1 (https=) |
| EP (1) | EP4185607A1 (https=) |
| JP (2) | JP7581385B2 (https=) |
| KR (2) | KR20230029480A (https=) |
| CN (1) | CN116157143A (https=) |
| AU (1) | AU2021312323A1 (https=) |
| BR (1) | BR112023000270A2 (https=) |
| CA (1) | CA3184717A1 (https=) |
| CL (1) | CL2023000087A1 (https=) |
| CO (1) | CO2023000097A2 (https=) |
| IL (1) | IL299701A (https=) |
| MX (1) | MX2023000303A (https=) |
| PE (1) | PE20231841A1 (https=) |
| TW (2) | TWI801942B (https=) |
| WO (1) | WO2022018186A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| UY40349A (es) * | 2022-07-13 | 2024-01-31 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Agonista dual de glp-1/gip, método de preparación y uso del mismo |
| TW202421645A (zh) | 2022-11-25 | 2024-06-01 | 丹麥商諾佛 儂迪克股份有限公司 | 如ｇｌｐ—１之肽治療劑的口服投與 |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| AR134436A1 (es) * | 2023-11-22 | 2026-01-14 | Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd | Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario |
| JP7755031B2 (ja) | 2023-11-30 | 2025-10-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬 |
| WO2025133045A1 (en) | 2023-12-22 | 2025-06-26 | Novo Nordisk A/S | Fermentation process |
| TW202535911A (zh) * | 2024-01-12 | 2025-09-16 | 大陸商杭州中美華東製藥有限公司 | 長效glp-1/gip雙激動劑的藥物組合物 |
| WO2025176999A2 (en) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Novel compounds |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2300035T3 (en) | 2008-06-17 | 2015-11-16 | Univ Indiana Res & Tech Corp | Mixed GIP-based agonists for the treatment of metabolic diseases and obesity |
| CN102325539A (zh) | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| EP2512518A1 (en) | 2009-12-16 | 2012-10-24 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
| EP2588127A4 (en) | 2010-06-24 | 2014-06-11 | Univ Indiana Res & Tech Corp | DIPEPTIDE-NETWORKED MEDICAL ACTIVE SUBSTANCES |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| SG191252A1 (en) * | 2010-12-22 | 2013-07-31 | Marcadia Biotech Inc | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| WO2012167744A1 (en) | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| EP3542790B1 (en) * | 2012-03-22 | 2023-09-13 | Novo Nordisk A/S | Compositions comprising a delivery agent and preparation thereof |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| HRP20180936T1 (hr) | 2012-06-21 | 2018-12-14 | Indiana University Research And Technology Corporation | Analozi glukagona koji pokazuju aktivnost prema receptoru za gip |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| CN105324125A (zh) | 2013-03-15 | 2016-02-10 | 印第安纳大学研究及科技有限公司 | 具有长效的前体药物 |
| JP6672140B2 (ja) * | 2013-05-02 | 2020-03-25 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１化合物の経口投薬 |
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| HK1226084A1 (zh) | 2013-08-16 | 2017-09-22 | Medimmune Limited | 用於治疗糖尿病的gip和glp-1受体双重激动剂 |
| WO2015035419A1 (en) | 2013-09-09 | 2015-03-12 | Hoffmann-La Roche Inc. | Dosages of gip/glp-1 co-agonist peptides for human administration |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| WO2016049174A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Lipidated amide-based insulin prodrugs |
| WO2016077220A1 (en) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Gip/glp-1 co-agonist peptides for human administration |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| JO3575B1 (ar) | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016131893A1 (en) | 2015-02-18 | 2016-08-25 | Medimmune Limited | Incretin fusion polypeptides |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| WO2017204219A1 (ja) | 2016-05-24 | 2017-11-30 | 武田薬品工業株式会社 | ペプチド化合物 |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
| KR102379958B1 (ko) | 2018-05-04 | 2022-04-01 | 노보 노르디스크 에이/에스 | Gip 유도체 및 이의 용도 |
| EP3826662B9 (en) | 2018-07-23 | 2025-02-19 | Eli Lilly and Company | Method of using a gip/glp1 co-agonist for diabetes |
| CN120754229A (zh) | 2018-07-23 | 2025-10-10 | 伊莱利利公司 | 使用gip/glp1共激动剂用于治疗的方法 |
| CN112469731B (zh) | 2018-07-23 | 2024-11-29 | 伊莱利利公司 | Gip/glp1共激动剂化合物 |
| MX2021012277A (es) * | 2019-04-11 | 2021-11-12 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Agonista multireceptor y uso medico del mismo. |
| CN110642935A (zh) | 2019-09-25 | 2020-01-03 | 成都奥达生物科技有限公司 | 一种替瑞帕肽类似物 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| MX2023000303A (es) | 2020-07-22 | 2023-02-09 | Novo Nordisk As | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. |
-
2021
- 2021-07-22 MX MX2023000303A patent/MX2023000303A/es unknown
- 2021-07-22 IL IL299701A patent/IL299701A/en unknown
- 2021-07-22 US US17/383,192 patent/US20220177538A1/en not_active Abandoned
- 2021-07-22 KR KR1020217034342A patent/KR20230029480A/ko not_active Ceased
- 2021-07-22 PE PE2023000026A patent/PE20231841A1/es unknown
- 2021-07-22 TW TW110126883A patent/TWI801942B/zh active
- 2021-07-22 BR BR112023000270A patent/BR112023000270A2/pt unknown
- 2021-07-22 US US18/017,041 patent/US20230272029A1/en active Pending
- 2021-07-22 TW TW111150185A patent/TW202315883A/zh unknown
- 2021-07-22 CA CA3184717A patent/CA3184717A1/en active Pending
- 2021-07-22 JP JP2022577750A patent/JP7581385B2/ja active Active
- 2021-07-22 WO PCT/EP2021/070485 patent/WO2022018186A1/en not_active Ceased
- 2021-07-22 CN CN202180059832.9A patent/CN116157143A/zh active Pending
- 2021-07-22 EP EP21749558.9A patent/EP4185607A1/en active Pending
- 2021-07-22 AU AU2021312323A patent/AU2021312323A1/en active Pending
- 2021-07-22 KR KR1020217034294A patent/KR102446310B1/ko active Active
-
2022
- 2022-01-12 US US17/574,079 patent/US11779648B2/en active Active
- 2022-11-04 US US17/980,990 patent/US20230120597A1/en not_active Abandoned
-
2023
- 2023-01-05 CO CONC2023/0000097A patent/CO2023000097A2/es unknown
- 2023-01-09 CL CL2023000087A patent/CL2023000087A1/es unknown
-
2024
- 2024-10-24 JP JP2024187587A patent/JP2025020197A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230029480A (ko) | 2023-03-03 |
| WO2022018186A1 (en) | 2022-01-27 |
| EP4185607A1 (en) | 2023-05-31 |
| JP7581385B2 (ja) | 2024-11-12 |
| JP2025020197A (ja) | 2025-02-12 |
| BR112023000270A2 (pt) | 2023-01-31 |
| US20230272029A1 (en) | 2023-08-31 |
| US20220125940A1 (en) | 2022-04-28 |
| MX2023000303A (es) | 2023-02-09 |
| AU2021312323A1 (en) | 2023-02-02 |
| US20230120597A1 (en) | 2023-04-20 |
| TWI801942B (zh) | 2023-05-11 |
| KR102446310B1 (ko) | 2022-09-23 |
| US11779648B2 (en) | 2023-10-10 |
| TW202315883A (zh) | 2023-04-16 |
| CO2023000097A2 (es) | 2023-03-27 |
| TW202208411A (zh) | 2022-03-01 |
| IL299701A (en) | 2023-03-01 |
| CL2023000087A1 (es) | 2023-07-07 |
| KR20220012840A (ko) | 2022-02-04 |
| US20220177538A1 (en) | 2022-06-09 |
| CA3184717A1 (en) | 2022-01-27 |
| JP2023534131A (ja) | 2023-08-08 |
| CN116157143A (zh) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231841A1 (es) | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral | |
| PE20231842A1 (es) | Coagonistas de los receptores de glp-1 y gip | |
| TWI810606B (zh) | Gip/glp1共促效劑化合物 | |
| JP7211712B2 (ja) | グルカゴン受容体アゴニスト | |
| JP7605747B2 (ja) | 修飾されたｇｉｐペプチド類似体 | |
| JP7280949B2 (ja) | タンパク質チロシン－チロシン類縁体およびそれを使用する方法 | |
| CN103596972B (zh) | 多肽 | |
| CN104945500B (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| CN104583232B (zh) | 展现gip受体活性的胰高血糖素类似物 | |
| RU2559320C2 (ru) | Новые аналоги глюкагона | |
| JP2022031787A (ja) | グルカゴン及びｇｌｐ－１共アゴニスト化合物 | |
| CN105324397B (zh) | 胰岛素-肠促胰岛素缀合物 | |
| AU2007331257B2 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2022130522A (ja) | 新規のアミリン及びカルシトニン受容体アゴニスト | |
| TW202415675A (zh) | 腸促胰島素(incretin)類似物及其用途 | |
| JP2016512213A5 (https=) | ||
| JP2012512903A5 (https=) | ||
| JP2013505221A (ja) | 長時間作用性ｙ２受容体アゴニスト | |
| JP2017534593A (ja) | オキシントモジュリン類似体 | |
| JP2014518207A (ja) | 多置換インスリン | |
| RU2006120079A (ru) | Производные глюкагоноподобного пептида-1 (glp-1) | |
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| JP2023511441A (ja) | Ｇｉｐ／ｇｌｐ１共アゴニスト化合物 | |
| CN120981479A (zh) | Gip/glp1/gcg三受体激动剂及其用途 | |
| CN119173275A (zh) | Glp-1多肽的前药及其用途 |